Abstract: Ethanone oximes represented by the following general formula: ##STR1## wherein R.sup.1 represents a cycloalkyl group, aryl group, aralkyl group, aryloxy group, aralkyloxy group, arylthio group or aryl sulfonyl group, those groups being optionally substituted with a substituent selected from an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms and a halogen atom, piperidino group, piperazino group, 4-alkyl substituted piperazino group, imidazolyl group 4-alkyl substituted imidazolyl group or substituted amino group,R.sup.2 represents a hydrogen atom or an alkoxy group having 1 to 3 carbon atoms, andR.sup.3 represents a piperidino group, piperazino group or 4-alkyl substituted piperazino group, orR.sup.1 and R.sup.2 together with a phenyl group to which they are attached may form a phenothiazin-2-yl group, N-acetyl-phenothiazin-2-yl group, thianthren-2-yl group, dibenzothiophen-3-yl group, dibenzofuran-3-yl group or a group of the formula: ##STR2## wherein R.sup.

Abstract: Compounds of Formula (I) and (II): ##STR1## are HMG-CoA reductase inhibitors.

Abstract: Ethanone oximes represented by the following general formula: ##STR1## wherein R.sup.1 represents a cycloalkyl group, aryl group, aralkyl group, aryloxy group, aralkyloxy group, arylthio group or aryl sulfonyl group, those groups being optionally substituted with a substituent selected from an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms and a halogen atom, piperidino group, piperazino group, 4-alkyl substituted piparazino group, imidazolyl group, 4-alkyl substituted imidazolyl group or substituted amino group,R.sup.2 represents a hydrogen atom or an alkoxy group having 1 to 3 carbon atoms, andR.sup.3 represents a piperidino group, piperazino group or 4-alkyl substituted piperazino group, orR.sup.1 and R.sup.2 together with a phenyl group to which they are attached may form a phenothiazin-2-yl group, N-acetyl-phenothiazin-2-yl group, thianthren-2-yl group, dibenzothiophen-3-yl group, dibenzofuran-3-yl group or a group of the formula: ##STR2## wherein R.sup.

Abstract: The present invention deals with dibenzo-oxocin-, dibenzo-thiocin-, dibenzo-azocin- and dibenzocyclo-octenamine derivatives suitable for use as antipsychotic compounds without extra-pyrimidal side-effects.

Abstract: Drugs with high anticonvulsant and analgesic activities constituted by symmetrical .beta.-dialkoxyiminocycloalklene derivatives in which the imine double bonds are conjugated with the cyclic double bond or bonds belonging to one or more fused benzene rings.

Abstract: Chemical compounds are provided that are novel 5,8-dichloro-4-hydroxy-1-[(aminoalkyl)amino]-9,10-anthracenediones (I), as well as a method for their production, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds in dosage form. Compounds of the invention have pharmacological properties and are useful antimicrobial agents and antitumor agents.

Abstract: Treatment of patients suffering from cancer, acquired immuno deficiency syndrome, multiple sclerosis, by administration of a serotonin antagonist, the administration taking place once a day during the evening, preferably after sunset.

Abstract: Novel 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds are disclosed. The compounds have the property of inhibiting calcium induced contraction of the smooth muscle.

Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Abstract: Propylamines of the formula (I): ##STR1## and isomers thereof, particularly those enantiomers and racemates relative to the chiral carbon indicated by an asterisk (*). The propylamines can be used for the treatment of hypertension or angina in humans. A is pyrrolidine, piperidine or morpholine and B is an aromatic heterocycle, aromatic carbocycle or saturated carbocycle.

Abstract: A new method of treating a patient suffering smooth muscle spasm comprises administering to the patient an effective amount of anti-spasmodic compound having the general formula: ##STR1## where R is selected from the group consisting of: ##STR2## wherein W is CH.sub.2, NH, O or S, ##STR3## wherein Y is an alicyclic ring ring having 3-12 carbon atoms, and ##STR4## the total number of carbon atoms in R is equal to or less than 20. Furthermore, m is an integer from 1 to 4, n is an integer from 1 to 4, p is an integer from 1 to 4 and q is an integer from 1 to 4. X may be nonexistent or may be 0, S, NH or CH.sub.2 or salts thereof. However, when X is nonexistent the terminal group in both the n-chain and the p-chain is a methyl group provided that a is zero or 1 and when a is 1, X is selected from the group consisting of 0, S, and CH.sub.

Abstract: 10,11-Dihydro-5H-dibenzo[a,d]cycloheptadiene derivatives of the formula I ##STR1## where R.sup.1 and R.sup.2 have the meanings stated in the description, and their preparation are described. The novel substances are useful for the treatment of disorders.

Abstract: Treatment of patients suffering from acquired immuno deficiency syndrome, multiple sclerosis, Alzheimer's disease, by administration of a serotonin antagonist, said administration taking place once a day during the evening.

Abstract: This invention relates to novel heterocyclic derivatives bearing an amino group and to processes for making said compounds.More particularly this invention provides novel heterocyclic compounds the hetero ring of which has two hetero atoms, the same or different, substituted with a free or substituted amino group.These compounds are useful as active ingredients of drugs.

Abstract: Pharmaceutical compositions comprising 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds and the use of 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds for treatment of certain cardiovascular disorders are disclosed.

Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Abstract: Pharmaceutical compositions comprising 4-(dibenzo[a,d]cycloalkenyl)piperazine compounds and the use of said piperazine compounds for treatment of certain cardiovascular disorders are disclosed.

Abstract: A (7S,9S) isomer or its racemic modification of the aminonaphthacene derivative of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom, a hydroxyl group or a lower alkoxy group, R.sup.2 is a hydrogen atom or a hydroxyl group, R.sup.3 and R.sup.4 are each a lower alkoxy group or, when taken together, represent an ethylenedioxy group or an oxo group, A is an ethylene group optionally bearing at least one lower alkyl and Q is a hydroxyl group, a lower alkoxy group or a dimethylamino group, or an acid addition salt thereof, which is useful as an anti-tumor agent.

Abstract: Piperidylidene derivatives of formula ##STR1## wherein n is 2 or 3, R.sub.1 comprises a tricyclic nucleus and R.sub.2 is hydrogen or an acid residue, useful in the treatment and prophylaxis of asthmatic conditions.

Abstract: The invention relates to novel [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-yl)oxy]ethanimidamid es and [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)oxy]ethanimidic acid hydrazides, their derivatives and their salts. The compounds are useful for the treatment and prevention of injury to the brain and of edema due to head trauma, stroke (particularly ischemic), arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, cerebral hemorrhage, cerebral tumors, encephalomyelitis, spinal cord injury, hydrocephalus, post-operative brain injury trauma, edema due to cerebral infections, various brain concussions and elevated intracranial pressure.

Abstract: The invention concerns 1,8-dihydroxy-9-anthrones substituted in the 10-position of the formula: ##STR1## in which: R.sub.1 represents a group taken from the set constituted by: wherein R.sub.2 represents H, C.sub.1-8 alkyl, C.sub.1-3 mono- or poly-hydroxyalkyl, carbamoly or phenyl,R.sub.3, R.sub.4, and R.sub.5 represent H, C.sub.1-8 alkyl, C.sub.3-8 mono- or poly-hydroxyalkyl, possibly interrupted by an oxygen, C.sub.3-6 cycloalkyl, or R.sub.3 and R.sub.4 form a divalent group: --(CH.sub.2).sub.(4 or 5) --, --(CH.sub.2).sub.2 --O--(CH.sub.2).sub.2 --, or --(CH.sub.2).sub.2 --N(R.sub.8)--(CH.sub.2).sub.2 --, R.sub.8 being H, --CH.sub.3, or --CH.sub.2 CH.sub.2 OH,R.sub.6 represents 13 CO.sub.2 R.sub.5, --CN, --CHO, --CONH.sub.2, or --CONH--CH.sub.2 OH,and R.sub.7 and R'.sub.7 are H or --CH.sub.3, and their optical isomers.Utilization of the compounds (I) in human or veterinary medicine, in particular in the treatment of psoriasis and of warts, and in cosmetics.

Abstract: The present invention relates to new tricyclic compounds of the formula: ##STR1## having valuable CNS and cardiovascular properties.

Abstract: 10-Substituted 5-cyanomethylene-dibenzo[a,d]-cycloheptenes, their pure cis- and trans-isomers, their N-oxides and their pharmaceutically tolerated addition salts with acids, processes for their preparation, therapeutic agents containing these compounds and their use as drugs, especially as sedatives, hypnotics or tranquilizers.

Abstract: A method of reducing stroke-induced neurological damage in a human patient comprising administering to said human patient an effective amount of a pharmaceutically acceptable neurological-damage-reducing serotonin antagonist.

Abstract: This invention relates to new N-(5-aminomethyl-2-oxazoline-2-yl)-N'-phenylureas, the method for producing them and their application in therapy, particularly in treating convulsions, rhythm troubles, ulcerous disorders or inflammatory or edematous conditions.The products of this invention have the general formula: ##STR1## wherein R.sub.1 and R.sub.2 independently represent an alkyl radical of C.sub.1 to C.sub.4, or a carbocyclic alkyl radical having 3 or less rings, or a carbocyclic radical having 3 or less rings; R.sub.1 and R.sub.2 can form, with the nitrogen atom to which they are attached, a 4 to 7 member heterocycle containing 1 or 2 nitrogen atoms and 1 or 0 oxygen atoms, said heterocycle can be substituted by R with R being an alkyl radical of C.sub.1 to C.sub.4, allyl, benzyl, pyridyl, phenyl substituted or not by one or more substituents such as halogen, trihalomethyl, alkyl of C.sub.1 to C.sub.4, hydroxy, or alkoxy having a C.sub.1 to C.sub.4 alkyl radical.